{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:24:38Z","timestamp":1767961478284,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T00:00:00Z","timestamp":1265673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s12032-009-9413-7","type":"journal-article","created":{"date-parts":[[2010,2,8]],"date-time":"2010-02-08T16:25:07Z","timestamp":1265646307000},"page":"211-218","source":"Crossref","is-referenced-by-count":36,"title":["miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines"],"prefix":"10.1007","volume":"28","author":[{"given":"Jingyi","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junlin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangkang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,9]]},"reference":[{"key":"9413_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281\u201397.","journal-title":"Cell"},{"key":"9413_CR2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","volume":"5","author":"L He","year":"2004","unstructured":"He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522\u201331.","journal-title":"Nat Rev Genet"},{"key":"9413_CR3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/nar\/gkl1032","volume":"35","author":"ZB Yu","year":"2007","unstructured":"Yu ZB, Jian ZF, Shen SH. Global analysis of microRNA target gene expression reveals that miRNA targets are lower expressed in mature mouse and Drosophila tissues than in the embryos. Nucleic Acids Res. 2007;35:152\u201364.","journal-title":"Nucleic Acids Res"},{"key":"9413_CR4","doi-asserted-by":"crossref","first-page":"D140","DOI":"10.1093\/nar\/gkj112","volume":"34","author":"S Griffiths-Jones","year":"2006","unstructured":"Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34:D140\u20134.","journal-title":"Nucleic Acids Res"},{"key":"9413_CR5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","volume":"431","author":"V Ambros","year":"2004","unstructured":"Ambros V. The functions of animal microRNAs. Nature. 2004;431:350\u20135.","journal-title":"Nature"},{"key":"9413_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-07-0573","volume":"7","author":"PE Blower","year":"2008","unstructured":"Blower PE, Chung JH, Verducci JS. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008;7:1\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"9413_CR7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1158\/1535-7163.MCT-09-0127","volume":"8","author":"E Salerno","year":"2009","unstructured":"Salerno E, Scaglione BJ, Coffman FD, Brown BD, Baccarini A, Fernandes H, et al. Correcting miR-15a\/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol Cancer Ther. 2009;8(9):268\u201392.","journal-title":"Mol Cancer Ther"},{"key":"9413_CR8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bcp.2008.06.007","volume":"76","author":"H Zhu","year":"2008","unstructured":"Zhu H, Wu H, Liu X, Evans BR, Medina DJ. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1\/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582\u20138.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"9413_CR9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2009.01.014","volume":"113","author":"T Boren","year":"2009","unstructured":"Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009;113(2):249\u201355.","journal-title":"Gynecol Oncol"},{"key":"9413_CR10","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1038\/onc.2008.72","volume":"27","author":"Z Lu","year":"2008","unstructured":"Lu Z, Liu M, Stribinskis V. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene. 2008;27:4373\u20139.","journal-title":"Oncogene"},{"key":"9413_CR11","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/sj.onc.1210856","volume":"27","author":"IA Asangani","year":"2008","unstructured":"Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27:2128\u201336.","journal-title":"Oncogene"},{"key":"9413_CR12","unstructured":"Li SZ. The compendium of materia medica. Beijing: People\u2019s Medical Publishing House; 1982 (originally published in the Ming Dynasty of China, 1578)."},{"key":"9413_CR13","first-page":"233","volume":"77","author":"SM Aronson","year":"1994","unstructured":"Aronson SM. Arsenic and old myths. R I Med. 1994;77:233\u20134.","journal-title":"R I Med"},{"key":"9413_CR14","first-page":"170","volume":"12","author":"HD Sun","year":"1992","unstructured":"Sun HD, Ma L, Hu XC, Zhang TD. Ai-lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin West Med. 1992;12:170\u20131.","journal-title":"Chin J Integr Chin West Med"},{"key":"9413_CR15","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","volume":"89","author":"ZX Shen","year":"1997","unstructured":"Shen ZX, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354\u201360.","journal-title":"Blood"},{"key":"9413_CR16","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1182\/blood.V94.10.3315.422k16_3315_3324","volume":"94","author":"C Niu","year":"1999","unstructured":"Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315\u201324.","journal-title":"Blood"},{"key":"9413_CR17","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","volume":"19","author":"SL Soignet","year":"2001","unstructured":"Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852\u201360.","journal-title":"J Clin Oncol"},{"issue":"9","key":"9413_CR18","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1073\/pnas.0813142106","volume":"106","author":"QY Zhang","year":"2009","unstructured":"Zhang QY, Mao JH, Liu P, Huang QH, Lu J, Xie YY, et al. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR\/ABL-associated leukemia. Proc Natl Acad Sci USA. 2009;106(9):3378\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"9413_CR19","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1182\/blood-2004-04-1433","volume":"104","author":"T Yin","year":"2004","unstructured":"Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104(13):4219\u201325.","journal-title":"Blood"},{"issue":"2 Suppl 1","key":"9413_CR20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/shem.2002.33611","volume":"39","author":"Z Chen","year":"2002","unstructured":"Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, et al. Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol. 2002;39(2 Suppl 1):22\u20136. (Review).","journal-title":"Semin Hematol"},{"issue":"9","key":"9413_CR21","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1073\/pnas.0813280106","volume":"106","author":"J Hu","year":"2009","unstructured":"Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, et al. Long-term efficacy and safety of all-trans retinoic acid\/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106(9):3342\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9413_CR22","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2005-08-3532","volume":"107","author":"V Mathews","year":"2006","unstructured":"Mathews V, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627\u201332.","journal-title":"Blood"},{"key":"9413_CR23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/annonc\/mdj019","volume":"17","author":"A Ghavamzadeh","year":"2006","unstructured":"Ghavamzadeh A, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and\/or chemotherapy. Ann Oncol. 2006;17:131\u20134.","journal-title":"Ann Oncol"},{"issue":"2","key":"9413_CR24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nsmb.1552","volume":"16","author":"S Gu","year":"2009","unstructured":"Gu S, Jin L, Zhang F, Sarnow P, Kay MA. Biological basis for restriction of microRNA targets to the 3\u2032 untranslated region in mammalian mRNAs. Nat Struct Mol Biol. 2009;16(2):144\u201350. (Epub 2009 Feb 1).","journal-title":"Nat Struct Mol Biol"},{"key":"9413_CR25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0092-8674(03)01018-3","volume":"115","author":"BP Lewis","year":"2003","unstructured":"Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115:787\u201398.","journal-title":"Cell"},{"key":"9413_CR26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.6026\/97320630002330","volume":"2","author":"J Manikandan","year":"2008","unstructured":"Manikandan J, Aarthi JJ, Kumar SD, Pushparaj PN. Oncomirs: the potential role of non-coding microRNAs in understanding cancer. Bioinformation. 2008;2:330\u20134.","journal-title":"Bioinformation"},{"key":"9413_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","volume":"6","author":"A Esquela-Kerscher","year":"2006","unstructured":"Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259\u201369.","journal-title":"Nat Rev Cancer"},{"key":"9413_CR28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ymeth.2007.11.001","volume":"44","author":"CC Esau","year":"2008","unstructured":"Esau CC. Inhibition of microRNA with antisense oligonucleotides. Methods. 2008;44:55\u201360.","journal-title":"Methods"},{"key":"9413_CR29","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/nar\/gki200","volume":"33","author":"AM Cheng","year":"2005","unstructured":"Cheng AM, Byrom MW, Shelton J. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33:1290\u20137.","journal-title":"Nucleic Acids Res"},{"key":"9413_CR30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.gt.3302654","volume":"13","author":"J Weiler","year":"2005","unstructured":"Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther. 2005;13:496\u2013502.","journal-title":"Gene Ther"},{"issue":"6","key":"9413_CR31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1042\/BC20080191","volume":"101","author":"B Lankat-Buttgereit","year":"2009","unstructured":"Lankat-Buttgereit B, G\u00f6ke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell. 2009;101(6):309\u201317.","journal-title":"Biol Cell"},{"key":"9413_CR32","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1126\/science.1097434","volume":"304","author":"S Yekta","year":"2004","unstructured":"Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004;304:594\u20136.","journal-title":"Science"},{"key":"9413_CR33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.cell.2005.07.031","volume":"122","author":"S Bagga","year":"2005","unstructured":"Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 2005;122:553\u201363.","journal-title":"Cell"},{"issue":"11","key":"9413_CR34","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nsmb.1709","volume":"16","author":"CY Chen","year":"2009","unstructured":"Chen CY, Zheng D, Xia Z, Shyu AB. Ago-TNRC6 triggers microRNA-mediated decay by promoting two deadenylation steps. Nat Struct Mol Biol. 2009;16(11):1160\u20136. (Epub 2009 Oct 18).","journal-title":"Nat Struct Mol Biol"},{"key":"9413_CR35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1074\/jbc.M707224200","volume":"283","author":"LB Frankel","year":"2008","unstructured":"Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, et al. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008;283:1026\u201333.","journal-title":"J Biol Chem"},{"key":"9413_CR36","first-page":"7081","volume":"63","author":"M Fraser","year":"2003","unstructured":"Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. Tsang. p53 is a determinant of X-linked inhibitor of apoptosis protein\/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 2003;63:7081\u20138.","journal-title":"Cancer Res"},{"key":"9413_CR37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7827-1-66","volume":"1","author":"M Fraser","year":"2003","unstructured":"Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol. 2003;1:66.","journal-title":"Reprod Biol Endocrinol"},{"issue":"12","key":"9413_CR38","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1158\/1078-0432.CCR-08-3053","volume":"15","author":"J Li","year":"2009","unstructured":"Li J, Huang H, Sun L, Yang M, Pan C, Chen W, et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 2009;15(12):3998\u20134008. (Epub 2009 Jun 9).","journal-title":"Clin Cancer Res"},{"issue":"1","key":"9413_CR39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1582-4934.2008.00556.x","volume":"13","author":"AM Krichevsky","year":"2009","unstructured":"Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med. 2009;13(1):39\u201353. (Review).","journal-title":"J Cell Mol Med"},{"issue":"Pt 4","key":"9413_CR40","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1042\/BST0370918","volume":"37","author":"SD Selcuklu","year":"2009","unstructured":"Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans. 2009;37(Pt 4):918\u201325. (Review).","journal-title":"Biochem Soc Trans"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-009-9413-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-009-9413-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-009-9413-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T19:07:07Z","timestamp":1590606427000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-009-9413-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,9]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["9413"],"URL":"https:\/\/doi.org\/10.1007\/s12032-009-9413-7","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,9]]}}}